T1	PROC 48 50	PD
#1	AnnotatorNotes T1	C1709518; Pharmacodynamic Study; Research Activity
T2	CHEM 411 422	antibiótico
#2	AnnotatorNotes T2	C0003232; Antibiotics; Antibiotic
T3	PROC 45 47	PK
#3	AnnotatorNotes T3	C0201734; Pharmacokinetic study; Research Activity
T4	PROC 586 588	PK
#4	AnnotatorNotes T4	C0201734; Pharmacokinetic study; Research Activity
T5	CHEM 92 104	metronidazol
#5	AnnotatorNotes T5	C0025872; metronidazole; Organic Chemical · Pharmacologic Substance
T6	DISO 145 192	infecciones producidas por Bacteroides fragilis
#6	AnnotatorNotes T6	C2205936; Infection by Bacteroides fragilis; Disease or Syndrome
T7	PROC 866 895	administró una monodosis oral
T8	CHEM 208 220	Metronidazol
#7	AnnotatorNotes T8	C0025872; metronidazole; Organic Chemical · Pharmacologic Substance
T9	CHEM 227 241	antimicrobiano
#8	AnnotatorNotes T9	C0003204; Anti-Infective Agents; Pharmacologic Substance
T10	DISO 272 295	infecciones anaeróbicas
#9	AnnotatorNotes T10	C0854328; Infection due to anaerobic bacteria; Disease or Syndrome
T11	CHEM 373 387	medicamentosos
#10	AnnotatorNotes T11	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T12	PROC 589 591	PD
#11	AnnotatorNotes T12	C1709518; Pharmacodynamic Study; Research Activity
T13	CHEM 500 512	metronidazol
#12	AnnotatorNotes T13	C0025872; metronidazole; Organic Chemical · Pharmacologic Substance
T14	PROC 663 665	PK
#13	AnnotatorNotes T14	C0201734; Pharmacokinetic study; Research Activity
T15	PROC 666 668	PD
#14	AnnotatorNotes T15	C1709518; Pharmacodynamic Study; Research Activity
T16	PROC 1519 1521	PK
#15	AnnotatorNotes T16	C0201734; Pharmacokinetic study; Research Activity
T17	CHEM 725 737	metronidazol
#16	AnnotatorNotes T17	C0025872; metronidazole; Organic Chemical · Pharmacologic Substance
T18	DISO 743 779	infecciones por Bacteroides fragilis
#17	AnnotatorNotes T18	C2205936; Infection by Bacteroides fragilis; Disease or Syndrome
T19	PROC 804 818	ensayo clínico
#18	AnnotatorNotes T19	C0008976; Clinical Trials; Research Activity
T20	PROC 1522 1524	PD
#19	AnnotatorNotes T20	C1709518; Pharmacodynamic Study; Research Activity
T21	CHEM 917 929	metronidazol
#20	AnnotatorNotes T21	C0025872; metronidazole; Organic Chemical · Pharmacologic Substance
T22	DISO 1151 1178	infecciones por B. fragilis
#21	AnnotatorNotes T22	C2205936; Infection by Bacteroides fragilis; Disease or Syndrome
T23	CHEM 1393 1405	metronidazol
#22	AnnotatorNotes T23	C0025872; metronidazole; Organic Chemical · Pharmacologic Substance
T24	PROC 1542 1553	tratamiento
#23	AnnotatorNotes T24	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T25	PROC 1 43	Evaluación farmacocinética/farmacodinámica
#24	AnnotatorNotes T25	C0201734; Pharmacokinetic study; Research Activity + C1709518; Pharmacodynamic Study; Research Activity
T26	PROC 69 88	administración oral
#25	AnnotatorNotes T26	C0001563; Administration, Oral; Therapeutic or Preventive Procedure | C1273553; Oral administration of treatment; Therapeutic or Preventive Procedure
T27	PROC 300 314	administración
#26	AnnotatorNotes T27	C1533734; Administration procedure; Therapeutic or Preventive Procedure
T28	PROC 482 496	administración
#27	AnnotatorNotes T28	C1533734; Administration procedure; Therapeutic or Preventive Procedure
T29	PROC 540 554	administración
#28	AnnotatorNotes T29	C1533734; Administration procedure; Therapeutic or Preventive Procedure
T30	PROC 685 699	administración
#29	AnnotatorNotes T30	C1533734; Administration procedure; Therapeutic or Preventive Procedure
T31	PROC 1446 1460	administración
#30	AnnotatorNotes T31	C1533734; Administration procedure; Therapeutic or Preventive Procedure
T32	DISO 1557 1580	infecciones anaeróbicas
#31	AnnotatorNotes T32	C0854328; Infection due to anaerobic bacteria; Disease or Syndrome
T33	Route 84 88	oral
#32	AnnotatorNotes T33	C1527415; Oral Route of Drug administration; Functional Concept
T34	LIVB 172 192	Bacteroides fragilis
#33	AnnotatorNotes T34	C0004663; Bacteroides fragilis; Bacterium
T35	Dose 327 342	dosis múltiples
T37	Dose 703 711	1.000 mg
T38	Frequency 712 721	cada 24 h
T39	LIVB 759 779	Bacteroides fragilis
#34	AnnotatorNotes T39	C0004663; Bacteroides fragilis; Bacterium
T40	Route 891 895	oral
#35	AnnotatorNotes T40	C1527415; Oral Route of Drug administration; Functional Concept
T41	Dose 899 913	500 y 1.000 mg
T42	PHYS 976 992	farmacocinéticos
#36	AnnotatorNotes T42	C0031327; Drug Kinetics; Physiologic Function
T51	Dose 1381 1389	1.000 mg
T53	Dose 1464 1472	1.000 mg
T54	Frequency 1473 1482	cada 24 h
T56	PHYS 12 27	farmacocinética
#37	AnnotatorNotes T56	C0031327; Drug Kinetics; Physiologic Function
T36	LIVB 837 848	voluntarios
#38	AnnotatorNotes T36	C0020155; Human Volunteers; Population Group
T44	LIVB 1167 1178	B. fragilis
#39	AnnotatorNotes T44	C0004663; Bacteroides fragilis; Bacterium
T43	PHYS 28 43	farmacodinámica
#40	AnnotatorNotes T43	C0851347; Pharmacodynamics; Biologic Function
T45	Duration 1256 1266	1,20± 0,8h
R1	Has_Route_or_Mode Arg1:T5 Arg2:T33	
R2	Used_for Arg1:T5 Arg2:T26	
R3	Causes Arg1:T34 Arg2:T6	
T46	Quantifier_or_Qualifier 242 253	de elección
R4	Has_Quantifier_or_Qualifier Arg1:T9 Arg2:T46	
R5	Has_Dose_or_Strength Arg1:T27 Arg2:T35	
T47	Observation 365 387	errores medicamentosos
#41	AnnotatorNotes T47	C0025115; Medication Error; Finding
R6	Causes Arg1:T27 Arg2:T47	
R7	Causes Arg1:T11 Arg2:T47	
R8	Used_for Arg1:T13 Arg2:T28	
T48	Observation 399 422	efecto post-antibiótico
T49	Observation 430 451	actividad bactericida
T50	Quantifier_or_Qualifier 452 477	concentración-dependiente
R9	Has_Quantifier_or_Qualifier Arg1:T49 Arg2:T50	
T52	Observation 108 126	intervalo ampliado
#42	AnnotatorNotes T52	C3495045; Medication dosing interval increased; Finding (?)
T55	Observation 516 554	intervalos ampliados de administración
#43	AnnotatorNotes T55	C3495045; Medication dosing interval increased; Finding (?)
R10	Overlap Arg1:T13 Arg2:T55	
R11	Overlap Arg1:T5 Arg2:T52	
R12	Used_for Arg1:T13 Arg2:T29	
R13	Causes Arg1:T13 Arg2:T49	
R14	Causes Arg1:T13 Arg2:T48	
R15	Has_Dose_or_Strength Arg1:T17 Arg2:T37	
R16	Has_Frequency Arg1:T17 Arg2:T38	
R17	Used_for Arg1:T17 Arg2:T30	
R18	Causes Arg1:T39 Arg2:T18	
R19	Experiences Arg1:T36 Arg2:T7	
R20	Has_Dose_or_Strength Arg1:T21 Arg2:T41	
R21	Has_Route_or_Mode Arg1:T21 Arg2:T40	
R22	Used_for Arg1:T21 Arg2:T7	
T57	CONC 1006 1024	método trapezoidal
#44	AnnotatorNotes T57	C5419715; Linear Trapezoidal Method; Intellectual Product (?)
T58	CONC 965 992	parámetros farmacocinéticos
#45	AnnotatorNotes T58	C0031328; Pharmacokinetic aspects; Functional Concept
T59	CONC 1041 1061	simulación de Markov
R23	Causes Arg1:T44 Arg2:T22	
R24	Has_Dose_or_Strength Arg1:T23 Arg2:T51	
R25	Has_Dose_or_Strength Arg1:T31 Arg2:T53	
R26	Has_Frequency Arg1:T31 Arg2:T54	
T60	Spec_cue 1489 1496	posible
T61	CONC 1510 1524	relación PK/PD
A1	Assertion T61 Speculated
T62	Quantifier_or_Qualifier 1525 1533	efectiva
A2	Assertion T62 Speculated
R38	Has_Quantifier_or_Qualifier Arg1:T61 Arg2:T62	
R39	Speculation Arg1:T60 Arg2:T61	
#46	AnnotatorNotes T62	C1704419;Effective; Qualitative Concept
T63	Spec_cue 555 565	permitiría
A3	Assertion T4 Speculated
R40	Speculation Arg1:T63 Arg2:T4	
A4	Assertion T12 Speculated
T64	Quantifier_or_Qualifier 592 601	efectivos
A5	Assertion T64 Speculated
#47	AnnotatorNotes T64	C1704419; Effective; Qualitative Concept
R41	Speculation Arg1:T63 Arg2:T12	
R42	Speculation Arg1:T63 Arg2:T64	
R43	Has_Quantifier_or_Qualifier Arg1:T4 Arg2:T64	
R44	Has_Quantifier_or_Qualifier Arg1:T12 Arg2:T64	
T65	CONC 1224 1228	Cmax
#48	AnnotatorNotes T65	C2347813; Cmax; Quantitative Concept
T66	CONC 1250 1254	tmax
#49	AnnotatorNotes T66	C2348796; Tmax; Quantitative Concept
T67	CONC 1270 1279	AUC0-24 h
T68	PROC 1139 1142	CIM
#50	AnnotatorNotes T68	C0427978; Minimum Inhibitory Concentration measurement; Laboratory Procedure
T69	PROC 1368 1371	CIM
#51	AnnotatorNotes T69	C0427978; Minimum Inhibitory Concentration measurement; Laboratory Procedure
T70	CONC 1358 1367	AUC0-24 h
T71	CONC 1129 1138	AUC0-24 h
#52	AnnotatorNotes T46	C0439608; elective; Temporal Concept (?) 
A6	Experiencer T36 Patient
